Regeneron制药公司从主要投资者那里获得的股份有所增加,并报告收入丰厚,提高了69.68B的市场上限。 Regeneron Pharmaceuticals saw increased holdings from major investors and reported strong earnings, boosting its $69.68B market cap.

DnB资产管理和Quantbot技术增加了其在生物制药公司Regeneron制药公司(NASDAQ:REGN)的持有量,而Pictet资产管理减少了其股份。 DnB Asset Management and Quantbot Technologies have increased their holdings in biopharmaceutical company Regeneron Pharmaceuticals (NASDAQ: REGN), while Pictet Asset Management reduced its stake. Regeneron报告说,第四季度的强劲收入为每股12.07美元,粗略估计,收入为37.9亿美元。 Regeneron reported strong fourth-quarter earnings of $12.07 per share, beating estimates, with revenue at $3.79 billion. 该公司的市场上限为696.8亿美元,分析师将其评为“多价购买”。 The company's market cap stands at $69.68 billion, and it is rated as a "Moderate Buy" by analysts.